國家衛生研究院 NHRI:Item 3990099045/11341
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2875888      線上人數 : 355
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/11341


    題名: Cardiovascular benefits of acarbose versus sulfonylureas in type 2 diabetic patients treated with metformin
    作者: Hsu, PF;Sung, SH;Cheng, HM;Shin, SJ;Lin, KD;Chong, K;Yen, FS;Yu, BH;Huang, CT;Hsu, CC
    貢獻者: Institute of Population Health Sciences
    摘要: Context: Althoughalpha-glucosidase inhibitor (AGI) has been shown to reduce the risk of myocardial infarction in patients with impaired glucose tolerance (IGT), the cardiovascular benefits of AGI in type 2 diabetes (T2D) remains unclear. Objective: We aimed to compare clinical outcomes of adding acarbose versus sulfonylureas to metformin therapy in T2D patients. Design, Setting, and Participants: The study population was drawn from the database of the Diabetes Pay-for-Performance (P4P) Program in Taiwan. Sulfonylureas and acarbose were respectively prescribed to 196,143 and 14,306 T2D patients during 2004-2015, who had been treated with metformin. A propensity score-matched cohort study was conducted. Patients were followed for clinical adverse events of all-cause mortality and hospitalizations of major atherosclerotic events (myocardial infarction and ischemic stroke), heart failure or hypoglycemia. Results: A total of 14,306 propensity score-matched pairs (55.8+/-13.1 years, 47.8% men) were enrolled in this analysis. Compared with sulfonylureas as the add-on therapy to metformin, the use of acarbose was associated with significantly lower risks of hospitalizations for major atherosclerotic events (hazard ratio and 95% confidence intervals: 0.69, 0.52-0.91), ischemic stroke (0.68, 0.49-0.94), and hypoglycemia (0.23, 0.08-0.71), after accounting for major confounding factors. Conclusions: In T2D treatment, use of acarbose as the add-on remedy to metformin was associated with lower risks of major atherosclerotic events, ischemic stroke, and hypoglycemia, compared with sulfonylurea.
    日期: 2018-10
    關聯: Journal of Clinical Endocrinology and Metabolism. 2018 Oct;103(10):3611-3619.
    Link to: http://dx.doi.org/10.1210/jc.2018-00040
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0021-972X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000448258100005
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85054459941
    顯示於類別:[許志成] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB30113697.pdf1014KbAdobe PDF398檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋